These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 22819791)

  • 21. Coadminstration of L. major amastigote class I nuclease (rLmaCIN) with LPD nanoparticles delays the progression of skin lesion and the L. major dissemination to the spleen in BALB/c mice-based experimental setting.
    Fakhraee F; Badiee A; Alavizadeh SH; Jalali SA; Chavoshian O; Khamesipour A; Mahboudi F; Jaafari MR
    Acta Trop; 2016 Jul; 159():211-8. PubMed ID: 27060774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
    Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
    FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Qualitative differences in the early immune response to live and killed Leishmania major: Implications for vaccination strategies against Leishmaniasis.
    Okwor I; Liu D; Uzonna J
    Vaccine; 2009 Apr; 27(19):2554-62. PubMed ID: 19428861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes.
    Badiee A; Jaafari MR; Khamesipour A
    Exp Parasitol; 2007 Feb; 115(2):127-34. PubMed ID: 16979165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
    Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S
    Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoliposomes containing Soluble Leishmania Antigens (SLA) as a novel antigen delivery system in murine model of leishmaniasis.
    Eskandari F; Talesh GA; Parooie M; Jaafari MR; Khamesipour A; Saberi Z; Abbasi A; Badiee A
    Exp Parasitol; 2014 Nov; 146():78-86. PubMed ID: 25246326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis.
    Ferreira JH; Gentil LG; Dias SS; Fedeli CE; Katz S; Barbiéri CL
    Vaccine; 2008 Jan; 26(5):677-85. PubMed ID: 18160187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
    Tewary P; Sukumaran B; Saxena S; Madhubala R
    Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CpG-containing ODN has a limited role in the protection against Toxoplasma gondii.
    Saavedra R; Leyva R; Tenorio EP; Haces ML; Rodríguez-Sosa M; Terrazas LI; Hérion P
    Parasite Immunol; 2004 Feb; 26(2):67-73. PubMed ID: 15225293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
    Mutwiri G; Benjamin P; Soita H; Babiuk LA
    Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice.
    Jaafari MR; Ghafarian A; Farrokh-Gisour A; Samiei A; Kheiri MT; Mahboudi F; Barkhordari F; Khamesipour A; McMaster WR
    Vaccine; 2006 Jul; 24(29-30):5708-17. PubMed ID: 16740346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis.
    Webb JR; Kaufmann D; Campos-Neto A; Reed SG
    J Immunol; 1996 Dec; 157(11):5034-41. PubMed ID: 8943412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunomodulatory effects associated with a live vaccine against Leishmania major containing CpG oligodeoxynucleotides.
    Wu W; Weigand L; Belkaid Y; Mendez S
    Eur J Immunol; 2006 Dec; 36(12):3238-47. PubMed ID: 17109471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis.
    Zimmermann S; Egeter O; Hausmann S; Lipford GB; Röcken M; Wagner H; Heeg K
    J Immunol; 1998 Apr; 160(8):3627-30. PubMed ID: 9558060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG + Q mix protects Balb/c mice from infection.
    Parody N; Soto M; Requena JM; Alonso C
    Parasite Immunol; 2004; 26(6-7):283-93. PubMed ID: 15541032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice.
    Iborra S; Parody N; Abánades DR; Bonay P; Prates D; Novais FO; Barral-Netto M; Alonso C; Soto M
    Microbes Infect; 2008; 10(10-11):1133-41. PubMed ID: 18603012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.
    Stacey KJ; Blackwell JM
    Infect Immun; 1999 Aug; 67(8):3719-26. PubMed ID: 10417129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice.
    Shah JA; Darrah PA; Ambrozak DR; Turon TN; Mendez S; Kirman J; Wu CY; Glaichenhaus N; Seder RA
    J Exp Med; 2003 Jul; 198(2):281-91. PubMed ID: 12874261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Self-assembling CpG DNA nanoparticles for efficient antigen delivery and immunostimulation.
    Rattanakiat S; Nishikawa M; Takakura Y
    Eur J Pharm Sci; 2012 Sep; 47(2):352-8. PubMed ID: 22771546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis.
    Agallou M; Margaroni M; Karagouni E
    Vaccine; 2011 Jul; 29(31):5053-64. PubMed ID: 21569815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.